SCHEDULE: Lynx1 Capital Discloses 15% Stake in TScan Therapeutics
Beneficial Ownership Disclosure
Lynx1 Capital Management LP and Weston Nichols have disclosed a 15.0% beneficial ownership stake in TScan Therapeutics, Inc.'s Voting Common Stock.
Summary
- Lynx1 Capital Management LP and Weston Nichols collectively beneficially own 7,857,347 shares of TScan Therapeutics, Inc. Voting Common Stock.
- This ownership represents 15.0% of the company's outstanding Voting Common Stock.
- The percentage is calculated based on 52,314,039 shares outstanding as of May 7, 2025.
- The shares are held by Lynx1 Master Fund LP, for which Lynx1 Capital Management LP acts as investment manager and Weston Nichols is the sole member of the general partner.
- The Reporting Persons share both voting and dispositive power over all 7,857,347 shares.
- The securities were not acquired or held for the purpose of changing or influencing control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.
Sentiment
Score: 7
Explanation: The disclosure of a significant 15.0% stake by an investment manager is generally viewed as a positive signal of institutional interest and potential confidence in the company's value, although the filing itself is purely factual.
Positives
- A significant 15.0% stake by an investment manager like Lynx1 Capital Management LP may signal institutional confidence in TScan Therapeutics, Inc.'s future prospects.
Risks
- The filing indicates that the Reporting Persons reserve the right to engage in activities solely in connection with a nomination under Rule 14a-11, which could imply potential future shareholder activism regarding board composition.
Future Outlook
The filing does not provide any forward-looking statements or guidance regarding TScan Therapeutics, Inc.'s operational or financial performance.
Industry Context
This filing reflects an investment manager's significant stake in a biotechnology company, a common occurrence in the sector where institutional investors often take positions in companies with promising pipelines or technologies.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional stake may increase investor confidence and potentially influence stock price due to perceived validation of the company's value.
- Management: The Reporting Persons' reservation of rights to engage in activities related to Rule 14a-11 nominations suggests a potential for future engagement with management regarding corporate governance or strategic direction.
Key Dates
| Date | Description |
|---|---|
| 2025-05-07 | Date as of which 52,314,039 shares of Voting Common Stock were reported outstanding in the Company's Definitive Proxy Statement on Schedule 14A. |
| 2025-05-14 | Date the Company's Definitive Proxy Statement on Schedule 14A was filed with the SEC. |
| 2025-06-30 | Date of event which required the filing of this statement (ownership threshold met). |
| 2025-08-14 | Date of filing of this Schedule 13G Amendment No. 2. |
Keywords
TScan Therapeutics, Lynx1 Capital Management, Weston Nichols, Beneficial Ownership, SEC Filing, Schedule 13G, Institutional Investor, Biotechnology, Common Stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.